STAT

The DEA wanted new suppliers of marijuana for research. Two years later, nothing has changed

Two years ago, the Trump administration said it would consider licensing new suppliers of marijuana grown to study its potential medical uses and risks. Scientists and lawmakers are still waiting.
Source: AP Photo/Robert Jordan

Two years ago, federal drug authorities said they would consider licensing new suppliers of marijuana grown for scientific purposes, a move seen as an acknowledgment of the need for additional rigorous research into potential medical uses and risks of cannabis and its components.

Hope you weren’t holding your breath.

The Drug Enforcement Administration still has not granted additional licenses for a after it announced it was open to approving one. The agency told STAT it had stopped accepting new applications and referred additional questions about licenses to the Justice Department, which did not return requests for comment.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks